Cereno: EAP data strengthen CS1 ahead of global Phase IIb study in PAH

▤ Summary

Cereno says EAP data strengthen its CS1 program ahead of a global Phase IIb study in pulmonary arterial hypertension. The title points to clinical development progress rather than a commercial software or corporate transaction event. The article text is not accessible, so only the headline can be used to infer the topic. This item is relevant to the life sciences sector but does not indicate a software product or vendor-facing procurement trigger.

▦ Linked Companies